Search Results

Vect-Horus announced the publication of a paper in the open-access scientific journal Pharmaceutics Vol 26.

VECT-HORUS today announced the appointment Pr. Xavier Declèves to its scientific advisory board (SAB).

Vect-Horus today announced it has entered into a global license agreement with Ionis Pharmaceuticals, Inc. (Nasdaq: IONS).

Vect-Horus, a privately held biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced it has entered into a global license agreement with Novo Nordisk A/S.

VECT-HORUS, a biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, announced the appointment of Dr Jean-Manuel Péan as Chief Scientific Officer.

RadioMedix and Vect-Horus are pleased to announce that they have successfully dosed the first patients in an exploratory Investigational New Drug (eIND) application to evaluate 68Ga-RMX-VH for the diagnostic of Glioblastoma Multiforme (GBM) and Pancreatic ductal adenocarcinoma (PDAC).

Vect-Horus announced the appointment of Pr. Frédéric Matonti to its scientific advisory board.

Horus Pharma, an independent French company leading player in ophthalmology, strengthens its international presence with the signature of eight distribution agreements – covering Romania, Portugal, Croatia, Turkey, Algeria, Qatar, Ireland and Bosnia – taking its total number of collaborations to 19.

VECT-HORUS, a biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, has announced the signing of a collaboration agreement with CERIMED (European Centre for Research in Medical Imaging) to support the preclinical development of VECT-HORUS’ theragnostic agents.

MDimune Inc. and Vect-Horus are please to announce today the signing of a Research Collaboration Agreement.